OptimizeRx Corporation
$6.70-$0.31 (-4.4%)
Last close · Data as of Nov 20, 2026
- Market cap
- $101.0M
- P/E
- 19.7x
- EV / EBITDA
- 6.3x
- Revenue
- $109.4M
- Net margin
- 4.7%
- ROCE
- 7.7%
Price chart
Technical chartScreen technicals →-50.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -25.0%
- 3M
- -15.8%
- 6M
- +34.8%
- 1Y
- -50.7%
- 5Y
- -90.7%
52-week range
Day change -$0.31 (-4.4%) from $7 to $7 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in OPRX, bought on each weekday since 2021.
News & filings
What OptimizeRx filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthReturn on equity rose from -17.2% to 4.0% between fiscal 2024 and fiscal 2025.
Concerns (1)
- The price fell as much as 71% from a high within the last year.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
OptimizeRx Corporation operates as a digital healthcare technology company.
Read moreShow less
OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 18.3M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $101.0M
- P/E
- 19.7x
- P/B
- 0.8x
- EV / EBITDA
- 6.3x
- EV / Sales
- 0.9x
- P/S
- 0.9x
- 52-week high
- $15.39
- 52-week low
- $4.54
Profitability
- Operating margin
- 11.0%
- Net margin
- 4.7%
- EBITDA margin
- 15.1%
- ROE
- 4.0%
- ROCE
- 7.7%
- ROIC
- 6.9%
- ROA
- 2.9%
- Asset turnover
- 0.62
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $109.4M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 18.8%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 20.6%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -125.5%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $18.7M
Solvency
- Current ratio
- 3.04
- Debt / Equity
- 0.20
- Debt / Assets
- 0.15
- CFO / Net profit
- 3.65
- Cash / Market cap
- 23.1%
Where the revenue went
Of every $100 of FY2025 revenue, $5 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $35.8M |
| Revenue | Gross profit | $73.6M |
| Gross profit | Selling, general and administrative | $57.2M |
| Gross profit | Other operating expenses | $4.3M |
| Gross profit | Operating income | $12.1M |
| Operating income | Pretax income | $7.0M |
| Operating income | Interest and other expense | $5.1M |
| Pretax income | Tax and other | $1.8M |
| Pretax income | Net income | $5.1M |
Revenue and net profit
Revenue grew 18.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $62.5M | -$11.4M |
| FY2023 | $71.5M | -$17.6M |
| FY2024 | $92.1M | -$20.1M |
| FY2025 | $109.4M | $5.1M |
Cash flows
FY2025: $18.7M from operations, $18.7M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $10.7M | $10.4M |
| FY2023 | -$7.2M | -$8.1M |
| FY2024 | $4.9M | $4.4M |
| FY2025 | $18.7M | $18.7M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $109.4M+18.8%1Y
- EBITDA
- $16.6M
- Net profit
- $5.1M
- Cash from operations
- $18.7M+282.8%1Y
- Free cash flow
- $18.7M+321.6%1Y
- Revenue CAGR, 3Y
- 20.6%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $109.4M | $16.6M | $5.1M | $18.7M | 4.0% | +18.8% | -125.5% |
Monthly returns
Month-by-month returns of OPRX across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $176.9M |
| Current assets | $64.7M |
| Non-current assets | $112.2M |
| Liabilities | $48.6M |
| Current liabilities | $21.3M |
| Non-current liabilities | $27.4M |
| Equity | $128.3M |
| Paid-in capital | $207.5M |
| Retained earnings | -$79.2M |
| Treasury stock | $0.00 |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; OPRX highlighted.
P/E against peers
OPRX trades at 19.7x earnings against a peer median of -1.5x.
Not shown (no positive earnings and no EV / Sales): Aldeyra Therapeutics, Inc., Aardvark Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| OptimizeRx CorporationOPRXthis company | $101.0M | 19.7x | 0.8x | 4.0% | 6.3x |
| The Joint Corp.JYNT | $117.3M | 40.3x | 7.8x | 19.3% | 118.2x |
| Aldeyra Therapeutics, Inc.ALDX | $106.2M | -3.1x | 2.4x | -76.5% | -1.6x |
| Cardiff Oncology, Inc.CRDF | $106.0M | -2.3x | 2.3x | -101.0% | -1.9x |
| Neuronetics, Inc.STIM | $101.6M | -2.6x | 4.5x | -174.3% | -5.8x |
| Definitive Healthcare Corp.DH | $95.7M | -0.7x | 0.3x | -49.4% | -0.7x |
| Heron Therapeutics, Inc.HRTX | $91.5M | — | 6.4x | -141.0% | — |
| Outset Medical, Inc.OM | $87.7M | -1.1x | 0.7x | -64.3% | -2.5x |
| Aardvark Therapeutics, Inc.AARD | $86.0M | -1.5x | 0.8x | -54.0% | -0.6x |
| Peer median | — | -1.5x | 2.4x | -70.4% | -1.6x |
Year-to-date ROI
OPRX since 1 January, against earlier years.
Historical volatility
OPRX's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -19.7% |
| FY2023 | -24.5% |
| FY2024 | -6.8% |
| FY2025 | 11.0% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $109.4M |
| Cost of revenueCost Of Revenue | $35.8M |
| Gross profitGross Profit | $73.6M |
| Operating expensesOperating Expense | $61.5M |
| Selling, general and administrativeSelling General And Administration | $57.2M |
| Other operating expensesOther Operating Expenses | — |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $4.3M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $4.3M |
| Total expensesTotal Expenses | $97.4M |
| Operating incomeOperating Income | $12.1M |
| Interest and other | |
| Pretax incomePretax Income | $7.0M |
| TaxTax Provision | $1.8M |
| Net incomeNet Income | $5.1M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $176.9M |
| Current assetsCurrent Assets | $64.7M |
| Non-current assetsTotal Non Current Assets | $112.2M |
| LiabilitiesTotal Liabilities Net Minority Interest | $48.6M |
| Current liabilitiesCurrent Liabilities | $21.3M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $27.4M |
| EquityTotal Equity Gross Minority Interest | $128.3M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $18.7M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $18.7M |
| Net income, continuing operationsNet Income From Continuing Operations | $5.1M |
| Depreciation and amortisationDepreciation And Amortization | $4.3M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $4.3M |
| Depreciation | $100.0k |
| Amortization cash flowAmortization Cash Flow | $4.2M |
| Amortization of intangiblesAmortization Of Intangibles | $4.2M |
| Stock-based compensationStock Based Compensation | $7.0M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Asset impairmentAsset Impairment Charge | $370.0k |
| Provision and write off of assetsProvisionand Write Offof Assets | — |
| Change in working capitalChange In Working Capital | $820.0k |
| Other non-cash itemsOther Non Cash Items | $1.1M |
| Investing cash flowInvesting Cash Flow | $70.0k |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $70.0k |
| Capital expenditureCapital Expenditure | — |
| Capital expenditure (reported)Capital Expenditure Reported | $130.0k |
| Purchase of PP&EPurchase Of PPE | -$60.0k |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$60.0k |
| AcquisitionsPurchase Of Business | — |
| DisposalsSale Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Purchase of investmentsPurchase Of Investment | — |
| Sale of investmentsSale Of Investment | — |
| Net investment purchases and salesNet Investment Purchase And Sale | — |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Financing cash flowFinancing Cash Flow | -$8.8M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$8.8M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | -$8.0M |
| Net debt issuedNet Issuance Payments Of Debt | -$8.0M |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$8.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$8.0M |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | — |
| Common stock repurchasedCommon Stock Payments | — |
| Share buybacksRepurchase Of Capital Stock | — |
| Stock options exercisedProceeds From Stock Option Exercised | $350.0k |
| Other financing chargesNet Other Financing Charges | -$1.1M |
| Change in cashChanges In Cash | $10.0M |
| Cash at the start of the yearBeginning Cash Position | $13.4M |
| Cash at the end of the yearEnd Cash Position | $23.4M |
| Free cash flowFree Cash Flow | $18.7M |
| Supplemental |
Learn while you research
Academy chapters picked for OptimizeRx Corporation and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read